Shares of Rezolute Inc. (RZLT) touched a new 52-week high of $8.06 last week amid FDA alignment on a significantly streamlined clinical development path for its lead asset, Ersodetug, in tumor-induced hyperinsulinism, as well as growing anticipation ahead of an upcoming trial catalyst in congenital hyperinsulinism.
Ersodetug is a fully human monoclonal antibody designed to help control blood sugar levels. It works in a unique way by attaching to insulin receptors in the body to reduce the effects of too much insulin or related hormones. It is administered by IV infusion every 2 to 4 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.